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Primary antibody deﬁciencyPurpose: Deﬁciencies in CD19 and CD81 (forming the CD19-complex with CD21 and CD225) cause a severe
clinical phenotype. One CD21 deﬁcient patient has been described. We present a second CD21 deﬁcient patient,
with amild clinical phenotype and compared the immunobiological characteristics of CD21 and CD19 deﬁciency.
Methods: CD21 deﬁciencywas characterized by ﬂowcytometric immunophenotyping and sequencing. Real-time
PCR, in vitro stimulation and next generation sequencing were used to characterize B-cell responses and afﬁnity
maturation in CD21−/− and CD19−/− B cells.
Results: A compound heterozygous mutation in CD21 caused CD21 deﬁciency. CD21−/− B cells responded
normally to in vitro stimulation and AIDwas transcribed. Afﬁnity maturation was less affected by CD21 than by
CD19 deﬁciency.
Conclusions: Both CD21 and CD19 deﬁciencies cause hypogammaglobulinemia and reduced memory B cells.
CD19 deﬁciency causes a more severe clinical phenotype. B-cell characteristics reﬂect this, both after in vitro
stimulation as in afﬁnity maturation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Genetic defects leading to primary antibody deﬁciencies (PAD) have
been described in both the B cell co-receptor complex and the comple-
ment cascade [1,2]. Previously 12 patients have been described with
deﬁciencies in CD19 and CD81, both part of the B cell co-receptor
complex [3–9]. Thus far, only a single patient with a deﬁciency in
CD21, also part of this complex, has been described [10]. All of these
patients exhibit hypogammaglobulinemia and impaired vaccination
responses and suffer from recurrent infections. However, age of disease
onset and severity of infections are variable.
CD19, CD81 and CD21 form, together with CD225, the B cell co-
receptor complex (Fig. 1) that enhances B-cell receptor (BR) mediated
signaling [11–14]. In this complex, CD81 (a tetraspanin) is essential
for CD19 expression on the B-cell membrane [4,15]. CD19 has a cyto-
plasmic tail with multiple tyrosine-kinase residues, needed for intracel-
lular signaling [11,13,16,17]. CD21 is also known as complement
receptor 2 (CR2) or EBV receptor [18–20]. It is expressed on both Bunology, Wytemaweg 80, 3015
der Burg).
. This is an open access article undercells and follicular dendritic cells [21]. The 145 kDa protein consists of
15 short consensus repeats, a transmembrane domain and a short
cytoplasmic tail [20,22]. The 19 exons of the CD21 gene are encoded
on chromosome 1q32 [20]. CD21 facilitates complement binding via
C3d-opsonized immune complexes and responses to low dose antigens
[18,20]. Functioning as a complement receptor, CD21 is involved in an-
tigen uptake and presentation, clearance of immune complexes and ap-
optotic cells, induction of tolerance, generation of immunological
memory, and survival, activation, and differentiation of B cells [21,23,
24]. Studies in mice have been done with CD21/CD35 knock-out
models, since these proteins are encoded by the same Cr2 locus [25].
Results from these studies indicate that CD21/CD35 deﬁciency leads to
decreased speciﬁc antigenic antibody responses [26–29] and increased
susceptibility to autoimmune diseases [30]. In several immunological
diseases such as HIV and autoimmune disorders increased CD21low/−
B-cell populations can be found [31–34].
Since CD81 is required for expression of CD19 on the plasma mem-
brane, patients with CD19 and CD81 deﬁciencies show a highly similar
phenotype with recurrent ear-nose-throat and respiratory infection
starting early in childhood [3–9]. Most patients develop accompanying
skin and gastro-intestinal infections. Upon ﬂowcytometric analysis, all
patients have normal B-, T- and NK-cell numbers, but reduced transi-
tional and memory B-cell numbers. Both CD81 deﬁciency and CD19the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic representation of the B cell co-receptor complex, in which CD81 is vital
for CD19 expression on the cell membrane [15], CD19 has an intracellular tail with multi-
ple tyrosine-kinase residues [11,16] and CD21 is able to connect to the BR via antigen
bound complement [18–21]. Co-activation of the BR and B cell co-receptor complex,
leads to dual receptor signaling [45].
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(SHMs) [7]. BR activation upon antigenic in vitro stimulation is impaired
in CD19 and CD81 deﬁcient cells. This emphasizes the necessity of CD19
and CD81 in the co-receptor complex to enable BR signaling.
The ﬁrst patient described with a CD21 deﬁciency [10] suffered
from recurrent upper respiratory tract infections in early childhood.
In his early twenties, this patient developed recurrent infections, in-
cluding respiratory tract and gastrointestinal infections. He had
hypogammaglobulinemia mainly affecting immunoglobulin (Ig)G;
IgA levels were slightly reduced and IgM levels were normal. Vacci-
nation responses to protein antigens were normal, but the response
to pneumococcal polysaccharide vaccination was moderately impaired.
Flowcytometric analysis revealed normal B–T and NK-cell numbers, but
reduced memory B cells. BR mediated signaling was affected in a
complement-dependent manner in case of sub-optimal stimulation
but unaffected upon strong stimulation. This underlines the comple-
ment receptor function of CD21 as an enhancer of B cell co-receptor
signaling.
Here we describe a second patient (13-year old male) with a
compound heterozygous CD21 deﬁciency resulting in hypo-
gammaglobulinemia. We compared the clinical and immuno-
biological characteristics of CD21 deﬁciency with CD19 deﬁciency.
We show that CD21 deﬁcient B cells have a normal BR mediated sig-
naling upon maximal stimulation in vitro, but slightly reduced SHM
frequency and class switch recombination (CSR).
2. Methods
2.1. Cell samples and ethical approval
Peripheral blood was obtained from the CD21 deﬁcient patient, age-
matched healthy controls and both parents of the patientwith informed
consent and according to the guidelines of the local Medical Ethics
Committees.
2.2. Flowcytometric immunophenotyping
Eight-color ﬂowcytometric immunophenotyping of peripheral
blood was performed on a Canto II (BD BioSciences, San Jose, CA,
USA). Data were analyzed using FACS Diva (BD Biosciences) and
Inﬁnicyt software (Cytognos, Salamanca, Spain). The followingantibodies were used: CD19-PerCP-Cy5.5 (SJ25C1), CD21-PECy7 (B-
ly4), IgD-biotin (IA6-2), CD27-APC (L128), CD38-APC-H7 (HB7; all
from BD Biosciences), CD24-PB (SN3; Exbio, Prague, Czech Republic),
CD45-PO (HI30; Invitrogen, Life Technologies, Carlsbad, CA, USA), IgG-
PE (K0103-41437) and IgA-FITC (IS11-8E10; both Miltenyi, Bergisch
Gladbach, Germany), polyclonal IgD-FITC and IgM-PE (Southern Bio-
technologies, Birmingham, AL, USA). CD21 absence was determined
using the following four CD21 antibodies: CD21-APC (CR2; BD Biosci-
ences), CD21-PB (LT21; Exbio), CD21-PE (LB21; Serotech, Hercules,
CA, USA), and CD21-PerCP (Bu32; BioLegend, San Diego, CA, USA).
2.3. Molecular analysis
DNA was isolated from blood granulocytes after separation using
Ficoll Hypaque (GE Healthcare, Little Chalfont, UK) according to the
manufacturer's instructions. Sequence analysis of CD21was performed
following PCR-ampliﬁcation of the coding regions with TaqGold™
(Life Technologies), followed by direct sequencing on an ABI Prism
3130 XL ﬂuorescent sequencer (Applied Biosystems, Bleiswijk, The
Netherlands). Primer sequences are available upon request. Sequences
were analyzed with CLC DNA-workbench software (CLCBio, Aarhus,
Denmark) and compared to theNCBI reference sequence (NG_013006).
2.4. Sorting of B-cell subsets and Ig transcript analysis
Naive, natural effector and memory B cells from 4 healthy controls
and the patient were sorted from post-Ficoll mononuclear cells on a
FACS Aria I (BD Biosciences) using the following antibodies: CD19-
PerCP-Cy5.5 (SJ25C1), CD27-APC (L128), CD3-FITC (SK7; all from BD
Biosciences) and polyclonal IgD-PE (Southern Biotechnologies). mRNA
was extracted usingGenelutemammalian total RNAKit (Sigma-Aldrich,
Saint Louis, MO, USA) and converted into cDNA. Taqman based RQ-PCR
with gene speciﬁc primers and probes (sequences available upon
request) was used to measure CD19, CD21, CD81, CD79A and PAX5 tran-
script levels as described before [3,4]. Expression levels were normal-
ized to ABL and PAX5.
2.5. Ca2+ ﬂux analysis
Post-Ficoll PBMCs from the CD21-deﬁcient patient and a healthy
control were used to determine free intracellular Ca2+ levels before
and after stimulation with anti-IgM as described previously [35]. Ca2+
inﬂuxes for the CD19 deﬁcient cells were determined previously
(Patient CD19-1.1) [3,4].
2.6. In vitro stimulation
PBMCs were cultured in 24-well plates (2 × 106 PBMCs per well) in
1 ml of IMDM culture medium, supplemented with 10% FCS, penicillin
(100 U/ml) and streptomycin (100 μg/ml), at 37 °C and stimulated
with anti-IgM (10 μg/ml) and anti-CD40 (10 μg/ml) and either hIL-4
(10 ng/ml) or hIL-10 (10 ng/ml) as described previously [7]. After 3
and after 6 days of culture cells were harvested and RNA was isolated.
This RNA was used to synthesize cDNA. Taqman based RQ-PCR with
gene speciﬁc primers and probes (sequences available upon request)
was used tomeasure CD19, AID andABL transcription levels as described
before [7]. AID levels were normalized to ABL and CD19 levels and com-
pared to expression levels in unstimulated cells to calculate the fold
increase in transcript levels.
2.7. Analysis of SHM and CSR
cDNA was prepared following RNA isolation of post-Ficoll PBMCs of
patients and age-matched healthy controls. This cDNAwas used to am-
plify IGA and IGG transcripts using VH1-6 consensus BIOMED-2 primers
[36] and Cγ (3′Cγ-CH1, [37]) and Cα (IGHA-R, [38]) primers. The
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the reverse B adaptor, the ‘TCAG’ key and multiplex identiﬁer (MID)
adaptor. PCR products were puriﬁed by gel extraction with the
QIAQuick gel extraction kit (Qiagen, Valencia, CA, USA) and Agencourt
AMPure XP beads (Beckman Coulter, Fullerton CA, USA). Subsequently,
the PCR concentration was measured using the Quant-iT™ PicoGreen®
dsDNA Assay Kit (Invitrogen). The puriﬁed PCR products were se-
quenced on the 454 GS Junior instrument using the GS Junior sequenc-
ing kit XL+, sequencing kit and PicoTiterPlate kit (454 Life Sciences,
Roche, Brandford CT, USA) according to the manufacturers recommen-
dations. Using the Antigen Receptor Galaxy Tool [39] sequences were
demultiplexed based on their MID sequence and quality checked.
FASTA ﬁles were uploaded in IMGT HighV-Quest [40]. For all sequences
the subclass of constant region was determined. Uniqueness of se-
quences was determined by V gene usage, amino acid sequence of the
CDR3 and C gene usage. Only unique, productive sequences were used
to calculate the frequency of mutated nucleotides in the VH gene
(from CDR1 until FR3).
In addition, IGG and IGA transcripts were ampliﬁed and analyzed as
described previously [41,42]. The mutation frequency was determined
for the VH segment, with exclusion of FR1, of each unique transcript.
2.8. Statistical analysis
Differences inmutation frequencies in SHMwere analyzed using the
nonparametric Mann–Whitney U-test (1 tailed) and transcript expres-
sion differences were analyzed by the two-tailed T test for independent
samples (P b 0.05 was considered signiﬁcant) in the GraphPad Prism
program (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Clinical and immunological presentation/case report
Our patient was a 13-year old boy, the second child of non-
consanguineous Dutch parents without family history of recurrent in-
fections or autoimmune diseases. He was referred to the department
of Pediatrics of the University Medical Centre Groningen for evaluation
hypogammaglobulinemia, which was discovered in the work-up for a
possible auto-immune origin of myalgia and rigidity. He did not have
a history of recurrent infections. No abnormalities were found upon
physical examination. Total serum IgG was 4.4 g/l (ref. 7–16 g/l for
age). IgG subclass analysis showed reduced IgG1 (2.5 g/l), reduced
IgG2 (0.5 g/l) and absent IgG4 (b0.1 g/l), whereas IgG3 was normal
(0.2 g/l). IgA levels were reduced (0.3 g/l (ref. 0.7–4 g/l)), as were IgM
levels (0.3 g/l, (ref. 0.4–2.3 g/l)). Serum IgE levels were in the high
normal range (109 g/l). He had been vaccinated according to the
DutchNational Vaccination Programandhis antibody titerswerewithin
the normal range, however additional booster vaccinations with subse-
quent determination of antibody levels have not been done. Autoim-
mune antibodies were negative. A C1q binding test was performed to
analyze presence of immune complexes; no abnormalities were found.
Analysis of B- and T- cell subsets revealed normal B–T- and NK-cellTable 1
Distribution of B-cell subsets in our CD21 deﬁcient patient at 13 years of age.
B cell subsets % Absolute coun
Transitional B (CD38high/CD24high) 9.5 52
Naive Mature (CD38dim/CD24dim/IgD+/CD27−) 81.0 446
MZ/Natural effector (CD38dim/CD24dim/IgD+/CD27+) 5.3 29
Memory (CD38dim/CD24dim/IgD−/CD27+) 1.6 9
IgM 23.0
IgG 39.5
IgA 37.5
Plasmablasts 0.3
Numbers indicated in bold are deviating from the normal values.numbers with slightly increased naive B cells and reduced memory B
cells (Table 1). However, none of the B cells expressed CD21 (Fig. 2A).
After three years of follow-up, now 16 years old, the patient is in
good health and has not experienced any (serious) infection. There
has been no further reduction in his Ig levels.
3.2. Flowcytometric immunophenotyping
The absence of CD21 expression on B cells was conﬁrmed using
different antibody–ﬂuorochrome combinations with multiple CD21
clones. Furthermore, following ﬁxation and permeabilization, CD21
could not be detected intracellularly either (data not shown). Analysis
of parental peripheral blood showed a decreased expression of CD21
on the surface of B cells in both parents, as compared to healthy controls
(Fig. 2A). Expression of CD19 on the cellmembranewas increased in the
CD21-deﬁcient patient and to a lesser extent in his parents (Fig. 2B).
CD81 expression was normal in both the patient and his parents, as
was CD35 (complement receptor 1) expression (data not shown).
3.3. Molecular analysis
Sequence analysis of all 19 exons and splice sites of the CD21 gene
revealed the presence of two heterozygous mutations (Fig. 2C, D): a
nonsense mutation in exon 2 (c.424CNT; p. Arg142Stop), and a two-
nucleotide deletion in exon 15 leading to a frame shift and a premature
stop codon (c.2777_2778delTA; p.Ile926SerfsX14). Bothmutations lead
to premature truncations of the protein in such way that the protein
lacks its transmembrane and cytoplasmic domain. Analysis of the par-
ents revealed that the mother was heterozygous for the mutation in
exon 2 and the father was heterozygous for the exon 15 mutation
(Fig. 2C). We concluded that these two truncating mutations lead to
the absence of CD21 expression on the cellmembrane and in the cytosol
of B cells.
3.4. Transcript levels of CD19, CD81 and CD21
To study the nature of the increased membrane expression of CD19
on CD21-deﬁcient cells, we determined the transcript levels of CD19,
CD21 and CD81 in CD27-IgD+ naive, CD27 + IgD+ natural effector
and CD27+ IgD−memory B cells of 4 healthy controls and the patient
(Fig. 3A). In all subsets from the patient, CD21 transcripts were severely
reduced. CD19 transcript levels in all the patient's subsets were compa-
rable to normal. CD81 and CD79A (anchor protein for the BR) transcript
levels in the patient, were in normal ranges in all subsets. The increased
expression of CD19 did not seem to result from altered transcriptional
regulation.
3.5. BR signaling
To study the effects of CD21 absence on BR signaling, we analyzed
Ca2+ inﬂux following stimulation of the patient's B cells with anti-
IgM. CD21-deﬁcient B cells showed a normal initial Ca2+ ﬂux from the
rough endoplasmatic reticulum into the cytoplasm, which is indicativet (cells/μl) Normal values (10–16 yr)
4–108 Within CD19+ gate
87–390 –
7–90 –
10–76 –
5–32% Within memory B-lymphocytes
25–74% –
14–47% –
Within CD19+ gate
Fig. 2. CD21 deﬁciency due to a compound heterozygousmutation. A. CD21membrane expression on B cells of the patient (in red), his parents (in purple), a healthy control (in blue) and
CD19 negative lymphocytes from the healthy control (in gray). B. CD19membrane expression on B cells of the patient (in red), his parents (in purple),a healthy control (in blue) and CD19
negative lymphocytes from the healthy control (in gray). C. Compound heterozygous mutations in the CD21 gene of the patient. Both parents carry one of both mutations. D. Schematic
representation of CD21 with 15 short consensus repeats (SCR). Position of the mutations found here (R142X and I926SfsX14) and the mutations found previously (c.1225+ 1 G N C and
W766X, in Italics) [10] are depicted.
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(Fig. 3B). In contrast, cells fromCD19-deﬁcient patients showed a defec-
tive Ca2+ ﬂux after maximal stimulation (Fig. 3B, [3,4]). Thus, signaling
via BR upon stimulation is normal in CD21 deﬁciency, but impaired in
CD19 deﬁciency.
3.6. In vitro stimulation
We studied whether the absence of CD21 affected the induction of
AID transcription, since AID is a major regulator in afﬁnity maturation
after antigenic stimulation [43]. We stimulated total PBMCs from the
CD21-deﬁcient patient in vitro for 3 or 6 days with anti-CD40, anti-
IgM and either hIL-4 or hIL-10 to induce transcription of AID. Using
real-timequantitative PCR the levels of AID transcriptswere determined
after stimulation and compared to unstimulated cells. To correct for the
amount of B cells present in each sample, we normalized for CD19 tran-
scripts. AID transcription was upregulated in B-cells of healthy controls
after 3 days of stimulation and was further enhanced after 6 days of
stimulation. Induction of AID transcription in B cells from the CD21-
deﬁcient patient was less than the normal control after 3 days of stimu-
lation. After 6 days of stimulation, the patient cells reached the same
levels in AID transcripts as the healthy control cells after 3 days
(Fig. 3C). These results show that AID transcription can be induced in
CD21-deﬁcient B cells, but at slower pace.
3.7. SHM analysis
To study the effect of CD21-deﬁciency on the frequency of SHM, we
prepared PBMC derived cDNA from the CD21-deﬁcient patient, age-
matched CD19-deﬁcient patients (6–12 years) and aged-matched
healthy controls (6–14 years). IGG and IGA transcripts were ampliﬁed
in a PCR reaction with speciﬁc primers and PCR products were se-
quenced using next-generation sequencing. The proportion of unique
productive sequences in the CD21 deﬁciency is comparable to the
healthy controls but lowered in the CD19 deﬁciency (data not shown).
SHM frequencies in transcripts of the CD21-deﬁcient patient wereslightly lower than those of age-matched controls (Fig. 4A), but signiﬁ-
cantly higher than in CD19-deﬁcient patients.
These ﬁndings are in line with previous analysis of these transcripts
in CD19 deﬁciency [3,4].
3.8. Analysis of CSR
To study Ig CSR, we determined the IGG and IGA constant region sub-
class usage in ampliﬁed IGG and IGA transcripts prepared from PBMC
derived cDNA. Compared to the healthy control, usage of downstream
IGG regions (IGG2 and IGG4) was reduced in CD21 deﬁciency, resulting
in increased IGG1 usage. In CD19 deﬁciency this increased IGG1 usage is
even more pronounced (Fig. 4B). IGA usage in CD21 deﬁciency was
comparable to normal, while in CD19 deﬁciency both IGA1 and IGA2
transcripts were overall strongly reduced and could only be ampliﬁed
by conventional cloning and sequencing (Fig. 4B).
4. Discussion
We describe the second patient with a CD21 deﬁciency caused by
two compound heterozygous mutations in the CD21 gene. Both muta-
tions cause a premature stop-codon resulting in truncated proteins
both lacking their transmembrane and cytoplasmic domains.
In contrast to the ﬁrst described CD21-deﬁcient patient, this patient
has no remarkable infections so far, despite his hypogammaglobulinemia.
However, at the age of 13, the previously described patient was asymp-
tomatic as well, developing recurrent infections only during early adult-
hood [10]. Both patients exhibit hypogammaglobulinemia, with normal
vaccination responses. This indicates that their immune system is capable
of mounting a seemingly normal immune response. With time, however,
infections haveoccurred in theﬁrst patient, resulting in theneed for intra-
venous immunoglobulin (IVIG) substitution. This in contrast with CD19
and CD81 deﬁciencies leading to (severe) recurrent infections already in
childhood, requiring frequent hospital admission, surgery for chronic si-
nusitis and IVIG at early age [3–9]. The CD19-deﬁcient patients often
Fig. 3. Transcription of CD19-complex members and response to in vitro stimulation. A. Expression levels of CD19, CD21, CD81 and CD79A in naive, natural effector and memory B cells of
controls (n= 4) and the CD21-deﬁcient patient, normalized to ABL. B. Ca2+ inﬂux in CD21 deﬁcient B cells resembles inﬂux in healthy control cells upon maximal stimulation with anti-
IgM. Ca2+ inﬂux in CD19-deﬁcient cells is severely reduced uponmaximal stimulationwith anti-IgM. Response to ionomycin is the same in all samples. Ca2+ inﬂux for the CD19deﬁciency
was performed by Van Zelmet al., previously [3]. B.AID transcription inCD21-deﬁcient B cells and healthy control B cells after in vitro stimulationwith anti-IgM, anti-CD40 and either hIL-4
or hIL-10. Expression after 3 and 6 dayswas normalized to ABL and compared to unstimulated cells from the same samples. CD19 expression levelswere used to correct for the amount of B
cells, present in the sample. In CD21-deﬁcient B cells, AID transcription can be induced.
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defects in CD19-complex can seriously impair B-cell function.
CD21 deﬁciency, like CD19 deﬁciency, does not lead to a decrease in
absolute B-, T- and NK-cell numbers. CD21 deﬁciency leads to increased
naive mature B cells and slightly decreased memory B cells, whereas
CD19 deﬁciency and CD81 deﬁciency result in a more prominent de-
crease in transitional (CD81) and memory B cells (both CD19 and
CD81). It seems that in CD21 deﬁciency an immune response is
mounted upon encounter of an antigenic stimulus, but with reduced
memory formation, whereas in CD19 and CD81 deﬁciency the immuneresponse is severely hampered. This is in line with the observation that
in CD19 andCD81 deﬁciency, signaling upon BR stimulation is impaired,
while calcium inﬂux upon maximal stimulation is unaffected in CD21
deﬁciency. Previously, Thiel et al. showed that calcium inﬂux in CD21
deﬁciency is impaired only in a complement dependent manner [10].
Thus, hypogammaglobulinemia in CD19 and CD81 deﬁciency can, at
least partially, be explained by defective BR signaling, whereas this is in-
tact in CD21 deﬁciency.
Interestingly, the CD21-deﬁcient B cells show an increase in CD19
expression on the plasma membrane which was not reﬂected on
Fig. 4. SHM and CSR in CD21 and CD19 deﬁciency compared to in aged matched donors (all samples between 6 years and 14 years of age), data frommultiple donors was combined for
controls (n=4) andCD19deﬁciency (n=4). A. SHM frequencydetermined inuniqueproductive sequencesN represents thenumber of uniqueproductive sequences thatwere analyzed.
B. Usage of IG constant gene segments determined for unique productive sequences. In CD19 deﬁciency no NGS data for IgA was available, sequences were all derived from cloning and
sanger sequencing. The number in the center of the plots represents the number sequences that were analyzed.
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also seen in CD21− cells found in auto-immune diseases [32–34] and
on CD21low/− cells in healthy individuals, although in health very few
of those cells can be detected. Increased CD19 expression was also
found in CD21/CD35 deﬁcient mice [44–46]. In contrast, in CD19 deﬁ-
ciency, CD21 expression is decreased on the plasma membrane. This
suggests that CD19 and CD21 expression levels are inter-connected.
The formation of a regulatory loop between CD19, CD21 and C3 has pre-
viously been postulated inmouse studies, which also showed that CD19
can function independent of complement activation [44,45]. Our results
indicate that this is not due to deregulated transcription. Possibly, the
increased CD19 expression is compensating for the loss of CD21where-
as in the case of the loss of CD19, CD21 cannot compensate and might
even be down regulated.
CD21 deﬁcient B cells respondnormal tomaximal stimulation, but in
the patient we see a profound hypogammaglobulinemia and a reduc-
tion in class switched memory B cells. After in vitro stimulation, AID
transcription could be induced in patients B cells (largely naive B
cells). The delay that we see in the patient sample could be caused by
the reduced number of memory B cells in the patient sample compared
to the healthy control, which show fast induction of AID after stimula-
tion. It seems that overstimulation or prolonged exposure to antigenic
stimuli can induce a proper response, but short or weak stimulation
does not evoke a response. This would be consistent with CD21 actingas a receptor for complement: lowering the threshold for a response
to stimulation [18–21,47].
Although the number ofmemory B cells is reduced in CD21 deﬁcien-
cy, they have a close to normal frequency of SHM and show a normal
ability for CSR, although they seem to switch preferentially to the
more upstream constant genes. This contrasts with the CD19 deﬁciency
where SHM frequency is substantially lower andwhere the skewing to-
wards IGG1 is more pronounced. We hypothesize that CD21 negative B
cells need strong or prolonged stimulation to evoke an antigenic re-
sponse. However, when this stimulation is strong enough, the cells
will respond with almost appropriate afﬁnity maturation. CD19-
deﬁcient B cells cannot respond to even these strong stimuli, resulting
in disturbed afﬁnity maturation.
In our patient, IgE levels are opposed to IgA and IgG levels in a
high-normal range. It seems that class-switching to IgE is not ham-
pered, showing that class-switch machinery functions correctly
and the reduced usage of downstream genes is rather a reﬂection
of an impaired secondary germinal center response than inability
of CD21 deﬁcient cells to switch to distantly located constant
regions.
Thus, in CD21deﬁciency the hypogammaglobulinemia and impaired
memory formation seem to result from a defect in signaling threshold
rather than from an intrinsic inability to form memory cells whereas
in CD19 and CD81 deﬁciency the clinical syndrome can be attributed
126 M.W.J. Wentink et al. / Clinical Immunology 161 (2015) 120–127to a defect in B-cell memory formation already during an early phase of
memory formation.
5. Conclusions
In conclusion, CD21 deﬁciency results in reduced numbers of mem-
ory B cells. However, the fraction of productive unique sequences is nor-
mal and SHM frequency is only slightly reduced. CSR is intact but shows
a slight preference for switching to upstream genes. An increased sig-
naling threshold seems to cause of an impaired immune response,
resulting in hypogammaglobulinemia and reduced memory B cells.
This might partially be restored by increased CD19 expression.
Prolonged or repeated antigen exposure can probably result in normal
antigen speciﬁc memory formation. In contrast, in CD19 deﬁciency im-
paired BR signaling is seen and therefore a defect in the early phase of
memory formation with a more severe clinical phenotype. Whereas
CD21 and CD19 belong to the same protein complex; the absence of
CD21 gives a milder immunological and clinical phenotype than CD19
deﬁciency.
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